Skip to main content
Journal cover image

Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.

Publication ,  Journal Article
Myhre, PL; Liu, Y; Kulac, IJ; Claggett, BL; Prescott, MF; Felker, GM; Butler, J; Piña, IL; Rouleau, JL; Zile, MR; McMurray, JJV; Ward, JH ...
Published in: Eur J Heart Fail
August 2023

AIMS: Adrenomedullin is a vasodilatory peptide with a role in microcirculatory and endothelial homeostasis. Adrenomedullin is a substrate for neprilysin and may therefore play a role in beneficial effects of sacubitril/valsartan (Sac/Val) treatment. METHODS AND RESULTS: Mid-regional pro-adrenomedullin (MR-proADM) was measured in 156 patients with heart failure with reduced ejection fraction (HFrEF) treated with Sac/Val and 264 patients with heart failure with preserved ejection fraction (HFpEF) randomized to treatment with Sac/Val or valsartan. Echocardiography and Kansas City Cardiomyopathy Questionnaire results were collected at baseline and after 6 and 12 months in the HFrEF cohort. Median (Q1-Q3) baseline MR-proADM concentrations were 0.80 (0.59-0.99) nmol/L in HFrEF and 0.88 (0.68-1.20) nmol/L in HFpEF. After 12 weeks of treatment with Sac/Val, MR-proADM increased by median 49% in HFrEF and 60% in HFpEF, while there were no significant changes in valsartan-treated patients (median 2%). Greater increases in MR-proADM were associated with higher Sac/Val doses. Changes in MR-proADM correlated weakly with changes in N-terminal pro-B-type natriuretic peptide, cardiac troponin T and urinary cyclic guanosine monophosphate. Increases in MR-proADM were associated with decreases in blood pressure, but not significantly associated with changes in echocardiographic parameters or health status. CONCLUSIONS: MR-proAD concentrations rise substantially following treatment with Sac/Val, in contrast to no change from valsartan. Change in MR-proADM from neprilysin inhibition did not correlate with improvements in cardiac structure and function or health status. More data are needed regarding the role of adrenomedullin and its related peptides in the treatment of heart failure. CLINICAL TRIAL REGISTRATION: PROVE-HF ClinicalTrials.gov Identifier: NCT02887183, PARAMOUNT ClinicalTrials.gov Identifier: NCT00887588.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

August 2023

Volume

25

Issue

8

Start / End Page

1396 / 1405

Location

England

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Neprilysin
  • Microcirculation
  • Humans
  • Heart Failure
  • Drug Combinations
  • Cardiovascular System & Hematology
  • Biphenyl Compounds
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Myhre, P. L., Liu, Y., Kulac, I. J., Claggett, B. L., Prescott, M. F., Felker, G. M., … Januzzi, J. L. (2023). Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan. Eur J Heart Fail, 25(8), 1396–1405. https://doi.org/10.1002/ejhf.2957
Myhre, Peder L., Yuxi Liu, Ian J. Kulac, Brian L. Claggett, Margaret F. Prescott, G Michael Felker, Javed Butler, et al. “Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.Eur J Heart Fail 25, no. 8 (August 2023): 1396–1405. https://doi.org/10.1002/ejhf.2957.
Myhre PL, Liu Y, Kulac IJ, Claggett BL, Prescott MF, Felker GM, et al. Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan. Eur J Heart Fail. 2023 Aug;25(8):1396–405.
Myhre, Peder L., et al. “Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.Eur J Heart Fail, vol. 25, no. 8, Aug. 2023, pp. 1396–405. Pubmed, doi:10.1002/ejhf.2957.
Myhre PL, Liu Y, Kulac IJ, Claggett BL, Prescott MF, Felker GM, Butler J, Piña IL, Rouleau JL, Zile MR, McMurray JJV, Ward JH, Solomon SD, Januzzi JL. Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan. Eur J Heart Fail. 2023 Aug;25(8):1396–1405.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

August 2023

Volume

25

Issue

8

Start / End Page

1396 / 1405

Location

England

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Neprilysin
  • Microcirculation
  • Humans
  • Heart Failure
  • Drug Combinations
  • Cardiovascular System & Hematology
  • Biphenyl Compounds